Breakthrough Science Requires Collaboration with Other Leaders in Gene Modification and Gene Therapy

"Enochian's efforts to pursue a cure for HIV using a novel gene-modified stem cell delivery system builds upon and extends previous successful research in this therapeutic space. While cautiously optimistic, I am excited to support these efforts to take on this high priority therapeutic challenge."

-David Hardy, MD, Adjunct Professor of Medicine at John Hopkins University School of Medicine, former Chief Medical Officer of Calimmune and Member of Enochian BioSciences' Scientific Advisory Board

Scripps Research, La Jolla, CA

Enochian and Scripps Research, one of the most notable medical research institutions in the world, entered a fee-for-service agreement to conduct a series of syngeneic and humanized mice studies. The research is being conducted in the laboratory of Phillippe Gallay, PhD, Professor of Immunology in the Scripps Research Department of Immunology and Microbiology. We believe this agreement will help advance the pre-clinical work necessary to obtain an Investigational New Drug application (IND) with the FDA and provide further valuable insights into the HIV program

Dong Sung An, MD, PhD, Professor at UCLA

Enochian also entered into an R&D agreement with Dong Sung An, MD, PhD, professor at UCLA. The team focuses on employing genetic modification techniques to make the human population resistant to HIV. Professor An will support the company's pre-clinical development program, including but not limited to viral vector design. UCLA is one of the leading academic centers in the field of HIV/AIDS research. Dr. An's prior work for vector designs for an efficient stem cell gene modification to develop anti-HIV will provide valuable insights to Enochian HIV program.

Hitachi Chemical Advanced Therapeutics Solutions (HCATS)

Enochian and HCATS (ex-PCT Cell Therapy Services), one of the world's largest cell therapy contract development and manufacturing organization (CDMO), signed an agreement to perform a manufacturing assessment of Enochian Biosciences' ENO-1001 in support of Enochian's efforts to develop the CMC section of ENO-1001. This agreement allows Enochian Biosciences to leverage HCATS' extensive experience in cell therapy development and manufacturing technology and wide-ranging manufacturing locations and we believe will allow us to provide clinical supply for our clinical trials in the future.